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Abstract Transmissible amyloid particles called prions are associated with infectious prion
diseases in mammals and inherited phenotypes in yeast. All amyloid aggregates can give rise to
potentially infectious seeds that accelerate their growth. Why some amyloid seeds are highly
infectious prion particles while others are less infectious or even inert, is currently not understood.
To address this question, we analyzed the suprastructure and dimensions of synthetic amyloid
fibrils assembled from the yeast (Saccharomyces cerevisiae) prion protein Sup35NM. We then
quantified the ability of these particles to induce the [PSI+] prion phenotype in cells. Our results
show a striking relationship between the length distribution of the amyloid fibrils and their ability
to induce the heritable [PSI+] prion phenotype. Using a simple particle size threshold model to
describe transfection activity, we explain how dimensions of amyloid fibrils are able to modulate
their infectious potential as prions.
DOI: https://doi.org/10.7554/eLife.27109.001
Introduction
The formation, processing, deposition and propagation of amyloid are at the center of a number of
disease-associated and functional biological phenomena. While some amyloid aggregates are asso-
ciated with devastating neurodegenerative diseases such as Alzheimer’s, Parkinson’s and prion dis-
eases (Eisenberg and Jucker, 2012; Knowles et al., 2014), other amyloid structures play many
functional biological roles such as bacterial biofilm formation (Larsen et al., 2007; Romero et al.,
2010; Chapman et al., 2002), mammalian melanosome organization (Berson et al., 2003) or epige-
netic inheritance in yeast (Tuite and Serio, 2010). Some amyloid aggregates are recognized as
prions because they form infectious particles, seeds that have the ability to be transmitted between
cells, organs, individuals or even species (Aguzzi et al., 2007; Prusiner, 1991; Sabate et al., 2015).
Prions can subsequently propagate by converting their soluble and correctly folded protein counter-
parts into the amyloid fold (Prusiner, 1991). However, this conversion process is not exclusive to
prions as amyloid growth by elongation at fibril ends of preformed seeds recruits and converts solu-
ble protein counterparts independently of the fibrillar seeds being transmissible prion particles or
non-infections amyloid.
The molecular and cellular mechanisms underlying prion infectivity are not fully understood, but
have been a key focus of research, particularly for the mammalian prion protein (PrP) which can be
transmitted between hosts across different species (Aguzzi et al., 2007; Weissmann et al., 2011).
Indeed, there is compelling evidence that the transmission of PrP amyloid between cattle with
Bovine Spongiform Encephalopathy and humans gave rise to a number of cases of so-called variant
Creutzfeldt-Jakob disease (Collinge, 1999). Furthermore, recent studies have shown that several dis-
ease-associated amyloid aggregates such as a-synuclein (Parkinson’s Disease), Tau (Alzheimer’s
Marchante et al. eLife 2017;6:e27109. DOI: https://doi.org/10.7554/eLife.27109 1 of 20
RESEARCH ARTICLE
disease and other tauopathies), amyloid-b (Alzheimer’s disease) and huntingtin (Huntington’s dis-
ease) are also capable of cross-cell transmission in a ‘prion-like’ manner (reviewed in [Aguzzi and
Lakkaraju, 2016]). The possibility that such aggregates might also be infectious under some circum-
stances has also been suggested (Jaunmuktane et al., 2015). These new data highlight a gap in the
knowledge of the factors that govern the infectious potential of amyloid particles in general. Why
are some amyloid fibrils highly infectious prion particles while others are less infectious or even
inert?
Amyloid fibrils are stable supramolecular structures characterized by the cross-beta molecular
architecture supported by intermolecular hydrogen bonds parallel to the fibril axis (Eisenberg and
Jucker, 2012; Knowles et al., 2014). Their formation is usually preceded by protein misfolding
events that result in the emergence of assembly-competent forms of amyloid-forming proteins (Fig-
ure 1). Amyloid formation then proceeds through nucleated polymerisation and fibril elongation
with growth occurring by templated addition of monomeric protein to the fibril ends (Serio et al.,
2000; Collins et al., 2004). The fragmentation of amyloid fibrils is an important secondary process
that divides fibrils and increases the number of growth competent fibril ends, which consequently
will accelerate amyloid growth (Xue et al., 2008; Knowles et al., 2009). This secondary process can
also increase the cytotoxic potential of amyloid particles (Xue et al., 2009a), as several studies have
Figure 1. The prion lifecycle. The de novo formation of a prion involves reversible protein misfolding and
consequential formation of amyloid conformers, which can assemble into small oligomeric species. Once this
assembly reaches a critical size (i.e. the nucleus size), further polymerisation is favoured and fibrils grow by
addition of protein monomer to their ends. This process can be accelerated by fibril fragmentation which
increases the number of fibril ends to which monomer can be added. In the yeast Saccharomyces cerevisiae this is
accomplished by the molecular chaperone Hsp104 and its co-chaperones and is essential to ensure a suitable
number of prion particles (propagons) of the appropriate size is generated, ensuring their transmission during cell
division. The process of fragmenting and transmitting prion particles is usually referred to as propagation.
DOI: https://doi.org/10.7554/eLife.27109.002
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correlated smaller amyloid species with higher amyloid toxicity (Tipping et al., 2015). Despite its
roles in disease-associated amyloid systems, fibril fragmentation is also crucial for ensuring the main-
tenance of functional amyloid such as yeast prions by producing sufficient number of growth compe-
tent amyloid particles to propagate the amyloid conformation and the prion phenotype
(Tanaka et al., 2006; Wang et al., 2011).
The budding yeast Saccharomyces cerevisiae encodes a large number of functional prion-forming
proteins, one of which is the translation termination factor Sup35 that, in its prion form, gives rise to
the associated prion phenotype [PSI+] (Tuite and Serio, 2010; Wickner, 1994; Patino et al., 1996).
Translation termination occurs efficiently in prion-free cells ([psi-]), but is impaired when Sup35
switches to its prion conformation (Wickner, 1994; Patino et al., 1996; Cox, 1965; Glover et al.,
1997), making the Sup35 prion protein an epigenetic regulator of gene expression. In this system,
the action of molecular chaperones, including Hsp104, catalyzes the fragmentation of the amyloid
fibrils and ensures that sufficient amyloid particles (referred to as propagons) exist during cell divi-
sion so that the prion phenotype is propagated to subsequent generations (Chernoff et al., 1995;
Glover and Lindquist, 1998) (Figure 1). Crucially, fully synthetic prion particles formed in vitro from
a recombinant form of Sup35 encompassing the first 253 residues of the protein (designated
Sup35NM) are capable of being transfected into yeast cells and inducing the [PSI+] prion phenotype
(King and Diaz-Avalos, 2004; Tanaka et al., 2004). This has provided us a highly tractable system
that has allowed us to carry out a quantitative biophysical assessment of the factors that govern the
infective potential of amyloid and prion particles.
Here, employing the Sup35NM/[PSI+] yeast prion system, we report a quantitative investigation
into the infective potential of prion particles. We ask whether the dimensions and physical properties
of prion particles can modulate their infective potential. This is achieved by quantifying the in vivo
response of yeast cells to synthetic Sup35NM prion particles formed in vitro with recombinant
Sup35NM and which have tailored length distributions by controlled fibril fragmentation. We use
quantitative atomic force microscopy (AFM) and single-particle image analysis to characterize the
morphology and suprastructure of the synthetic Sup35NM prion particles, and resolve their size dis-
tribution and particle concentration to a high quantitative detail. We then quantify the potential of
these synthetic prion particles to transfect yeast cells and induce the heritable [PSI+] state in vivo.
Our data show a striking relationship between the size distribution of prion particles and their ability
to confer the prion phenotype associated with these particles. Detailed analysis of this relationship
reveals that the ability to transfect and induce the [PSI+] phenotype is not identical for individual
Sup35NM prion particles of different lengths, and has allowed us to estimate the particle size thresh-
old for Sup35NM transfection of yeast cells using a simple modelling approach. Our results indicate
that the physical dimensions of otherwise identical prion particles are key parameters that are suffi-
cient to alter the infective potential of prion particles. These conclusions suggest possible routes to
reduce prion and prion-like infectivity of amyloid by aggregate size modification approaches, for
example by promoting the formation of large inert aggregates from transmissible particles or by
increasing the stability of fibrils to reduce the creation of transmissible particles by fibril fragmenta-
tion, in strategies to combat the transmission of prions and amyloid particles.
Results
In vitro formation and AFM imaging of Sup35NM amyloid fibrils
In order to analyze the effects of fibril dimensions on prion infectivity we first produced synthetic
Sup35NM prion particles in vitro from recombinant monomeric Sup35NM, and generated fibril sam-
ples with a range of length distributions. The yeast prion protein Sup35 can be subdivided into three
regions: N, M and C. The N (residues 1–123) and M region (124–253) are responsible for amyloid for-
mation and prion maintenance, while the C terminal region of the protein (residues 254–685) is
responsible for its translation termination function. When expressed in E. coli, the N + M regions
(Sup35NM, residues 1–253) are sufficient to confer the [PSI+] phenotype when transfected into [psi-]
yeast cells (King and Diaz-Avalos, 2004; Tanaka et al., 2004; Sparrer et al., 2000). Recombinant
Sup35NM protein monomers were therefore expressed in E. coli and purified under denaturing con-
ditions as described in Materials and methods. Sup35NM polymerisation reactions were carried out
in 20 mM sodium phosphate buffer, pH 7.4, 50 mM NaCl at a protein concentration of 10 mM to
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form Sup35NM amyloid fibril samples at a temperature of 30˚C, which is the standard laboratory
growth temperature for S. cerevisiae. Both de novo formation and polymerisation of Sup35NM
under these conditions were monitored in parallel in reactions containing the fluorescent amyloid
binding dye Thioflavin T (Figure 2a).
Under the conditions employed, the Sup35NM polymerization reaction progress curves showed a
sigmoidal shape expected for amyloid formation, with a lag phase of approximately 5 hr, followed
by an exponential growth phase of approximately 5–10 hr in length. The reactions reached the
upper plateau phase after approximately 20–30 hr. Analysis of the resulting amyloid fibrils using
AFM imaging after the reactions reached the upper plateau (Figure 2b, upper left image) showed
suprastructures consisting of large, intertwined networks of long fibrils. We next fragmented these
fibrils by controlled sonication (see Materials and methods, Figure 2b). After 5 s of mechanical per-
turbation by sonication, a number of shorter and more disperse fibrils and small fibril clusters com-
pared with non-fragmented initial samples were observed by AFM. An increasingly dispersed and
non-clustered fibril population was observed with further sonication. A range of sonication durations
were tested to generate a range of fibril sizes confirmed by AFM imaging (Figure 2b).
Figure 2. In vitro polymerization and fragmentation of Sup35NM prion fibrils. (a) Sup35NM polymerization monitored using the amyloid-binding dye
Thioflavin T. Five experimental replicates are plotted, with curves normalized to their upper baseline. (b) Representative atomic force microscopy
images of Sup35NM amyloid fibrils before (0 s) and after sonication. Samples were diluted 1:300 prior to deposition on the mica surface except for the
0 s sample. Images of 10 mm x 10 mm in scan size are shown together with 4 x further magnified views. The scale bar represents the length of 2 mm in all
images and arrows show examples of clusters of fibril particles.
DOI: https://doi.org/10.7554/eLife.27109.003
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Characterization of Sup35NM prion particles
We next quantified the size distribution of the Sup35NM prion particles using a combination of
sucrose density gradient analysis and semi-denaturing detergent agarose gel electrophoresis (SDD-
AGE) (Kryndushkin et al., 2003). These biochemical methods have been previously used to distin-
guish prion aggregates in cell populations that have the prion phenotype versus those that do not,
as well as to assess the occurrence of different prion conformational variants. Native sucrose density
gradient analysis of Sup35NM amyloid fibrils fragmented to different extents by controlled sonica-
tion (Figure 3a) showed a clear shift in relative aggregate size after sonication. As seen in Figure 3a,
fraction one containing monomeric Sup35NM was composed of less than 5% of total protein content
in all samples, indicating that the polymerisation reaction had reached near-completion, and the con-
trolled sonication had not caused increased free monomer concentration due to depolymerisation,
as seen previously in other amyloid-forming systems (Xue and Radford, 2013). The bulk of the fibril
material shifted from the heavier to lighter fractions when sonication time was increased, indicating
a reduction in the size distribution of the prion particles.
The differences in size distribution post-sonication were more difficult to detect when the fibril
samples were characterized by SDD-AGE (Figure 3b). SDD-AGE analysis is performed under semi-
denaturing conditions that do not disrupt the amyloid core of the fibril particles. Thus, the SDD-AGE
data, which showed the position of the core Sup35NM aggregates as broad bands, did not reveal
any change in electrophoretic mobility with increasing sonication duration after the first 15 s of soni-
cation. This may reflect the breakup of the large fibril network from the first 15 s of sonication as
seen in Figure 2b. However, the data demonstrate that SDD-AGE cannot distinguish further short-
ening of the amyloid particles or breakup of small fibril clusters (Figures 2b and 3a) after the initial
break-up of the fibril network. Importantly, the SDD-AGE analysis (Figure 3b) did indicate that the
relative aggregate size in the [PSI+] cell extract used as a control only overlap with the in vitro gener-
ated sample that was sonicated for more than 15 s, indicating that the in vivo prion particles do not
resemble the fibril network seen in the untreated synthetic sample (Figure 2b, 0 s). This result is cor-
roborated by the fact that the in vitro generated sample that was not treated (Figure 2b, 0 s) cannot
induce the [PSI+] phenotype, while the [PSI+] cell extract typically is able to induce 10–40% [PSI+]
cells when transfected into [psi-] yeast cells under the standard conditions for transfection employed
(Materials and methods, Figure 3—figure supplement 1). Interestingly, the in vivo formed prion
particles from the [PSI+] cell extract did overlap with the lower portions of the samples sonicated for
longer periods than 15 s on SDD-AGE, suggesting that the prion species present in vivo may be rep-
resented by the lower molecular weight species in the in vitro assembled and sonicated fibril sam-
ples. The efficiency of a [PSI+] cell extract to induce [PSI+] cells when transfected into [psi-] yeast cells
is highly variable due to many factors such as differences in protein expression levels of Sup35, the
prion strain variant present as well as the variable repertoire of chaperones and other cellular factors
that associate with the fibrils. Therefore, to isolate the effect of particle dimensions on their ability to
transfect cells, we next analyzed in detail the dimensions of the in vitro assembled and sonicated
fibril samples and assessed their ability to induce the [PSI+] state in [psi-] cells.
Size distribution and particle concentration quantification of Sup35NM
prion samples
To resolve the detailed length distribution and the size change of the amyloid particles in our sam-
ples in absolute length units, we next imaged and measured the length of individual particles using
AFM and carried out length distribution analysis (Xue and Radford, 2013) on the Sup35NM fibril
samples. This analysis was then used to estimate particle number concentration, particle widths (par-
ticle heights in AFM image data) and particle lengths for each individual synthetic prion sample. A
total of 72 images were collected and analyzed for 26 samples, with at least two images and a mini-
mum of 500 particles per sample analyzed to ensure sufficient numbers of fibril particles were taken
into account (see Table 1).
In general, increased time of controlled mechanical perturbation by sonication resulted in a
decrease of the mean particle size as previously shown (Xue and Radford, 2013; Xue et al.,
2009b), with longer sonication times producing smaller mean fibril lengths (Figure 4 and Figure 4—
figure supplement 1). This can also be seen in the sample particle length distributions (Figure 4a
and Figure 4—figure supplement 1), which show the presence of an increasing number of smaller
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Figure 3. Biochemical analysis of fragmented Sup35NM fibrils and their sizes. (a) Native sucrose density gradient analysis of sonicated Sup35NM fibrils.
Each group of bars corresponds to one time-point, showing the percentage of total protein present in each of the nine gradient fractions. For each
time point, three independent replicates were averaged. Error bars represent standard error of the mean. A representative Western blot for each of the
Figure 3 continued on next page
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particles when samples were sonicated for longer periods. As seen in Figure 4a, the average length
of the Sup35NM prion particles reduced from over 210 ± 21 nm to 75 ± 5 nm over the course of 16
min (960 s) of controlled sonication. We also analyzed the height across all particles, which is indica-
tive of the particle widths (Figure 4c). This showed that the average particle width remained largely
unchanged when sonication time was increased, with the mean height observed at 7.1 ± 0.5 nm. The
average dimensions of the fibril particles after extended periods of mechanical perturbation by soni-
cation is also comparable to that expected for protein filaments with tensile strength of 0.2 GPa
Figure 3 continued
time points is also shown. (b) SDD-AGE analysis, followed by immunoblotting, of the Sup35NM fibril samples. Samples sonicated for different periods
of time are shown in each lane. A cell extract of [PSI+] cells is shown on the left most lane for comparison.
DOI: https://doi.org/10.7554/eLife.27109.004
The following figure supplement is available for figure 3:
Figure supplement 1. Prion transfection efficiency of [PSI+] cell extract.
DOI: https://doi.org/10.7554/eLife.27109.005
Table 1. Quantitative analysis of Sup35NM amyloid fibril samples.
Sample and image analysis statistics for characterized Sup35NM amyloid fibril samples.















1 15 5 189.7 1805 7.0 27965 12.3
2 30 5 121.9 6110 6.1 64381 25.0
3 60 2 112.3 5500 6.2 63114 29.4
4 120 2 111.7 5814 6.9 79594 35.0
5 240 2 88.4 7478 7.2 88175 36.7
6 480 2 74.5 8564 7.8 91816 59.5
7 960 2 77.2 8604 8.1 92713 68.9
8 15 4 231.1 1560 6.7 24809 12.6
9 30 4 141.8 2699 6.5 33303 17.3
10 60 2 184.8 2003 7.2 31931 9.2
11 120 2 125.9 4562 7.1 63937 27.7
12 240 2 84.3 4169 7.0 48486 24.7
13 480 2 68.9 5662 7.5 57393 42.0
14 960 2 70.9 5717 7.8 62894 51.2
15 30 4 142.3 675 7.1 9353 6.7
16 60 3 131.8 1937 6.8 24348 13.1
17 120 2 161.0 1909 7.1 27013 23.5
18 240 2 87.0 4269 7.0 49000 21.9
19 480 3 88.8 2938 7.0 33342 21.6
20 960 2 85.7 4687 7.4 56457 35.6
21 30 6 160.5 3306 6.9 47476 -
22 60 4 150.0 3523 7.5 47590 -
23 120 2 184.2 2198 7.0 32565 -
24 240 2 133.3 1803 7.5 24158 -
25 480 2 150.6 1455 7.3 21163 -
26 960 2 64.3 8000 7.3 77914 -
DOI: https://doi.org/10.7554/eLife.27109.006
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undergoing sonication-induced scission (Huang et al., 2009). These observations are consistent with
the fact that the controlled mechanical perturbation resulted in a reduction in particle length, but
did not otherwise alter the individual fibril assemblies.
Taken together with the biochemical characterizations of the fibril samples, our results indicate
that non-sonicated in vitro generated Sup35NM amyloid particles form a suprastructure consisting
of large fibril networks that do not reflect the size and the suprastructure of prion particles present
in vivo in [PSI+] cells. The controlled sonication alters this suprastructure by initially dispersing the
fibril network into smaller clustered aggregates, and subsequently produces dispersed fibril particles
Figure 4. Single-particle analysis of Sup35NM fibril length distribution after controlled sonication. (a) Particle size distributions for seven representative
Sup35NM samples sonicated for different times. The occurrence of different particle sizes was normalized against the total number of particles traced
for each individual sample and plotted against particle length (blue lines). Sonication time and the number of fibrils analyzed for each sample are
displayed in each plot. (b) Relationship between mean particle length and sonication time. Each data point represents the mean of all individual
samples analyzed for a given time point. Error bars represent the standard error of the mean. (c) Relationship between mean particle height,
representing the width of the fibril particles, and sonication time. Each data point represents the mean of all individual samples analyzed for a given
time point. Error bars represent the standard error of the mean. The mean height of all values is represented by the solid red line, with its standard
error represented by the dotted red lines.
DOI: https://doi.org/10.7554/eLife.27109.007
The following figure supplement is available for figure 4:
Figure supplement 1. Particle length distributions for individual Sup35NM samples analyzed by AFM image analysis.
DOI: https://doi.org/10.7554/eLife.27109.008
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with size distributions overlapping with that of particles present in vivo in [PSI+] cells. Further sonica-
tion then proceeds to further reduce the length distribution of the resulting dispersed fibril particles,
but the mechanical perturbation employed did not otherwise change the width of these particles.
Influence of fibril particle concentration and size on prion transfection
efficiency
Lastly, we measured the ability of the synthetic fibril samples to induce the [PSI+] phenotype in vivo
in yeast cells. S. cerevisiae (74D-694 [psi-]) cells were transfected by 20 different fibril samples that
had their size distributions characterized in detail by AFM image analysis as described above
(Table 1, Figure 4—figure supplement 1). The fibril samples were added to the yeast transfection
reaction at the same time they were deposited on mica for the AFM analysis to eliminate the impact
of sample-to-sample particle size variations (as shown in Figure 4) on [PSI+] transfection efficiency
determinations. Figure 5a and b show the relationship between the average particle lengths of the
samples and their efficiencies in inducing the [PSI+] phenotype. Under the conditions employed, fibril
samples with average particle length ranging from 231 nm to 69 nm resulted in [PSI+] transfection
efficiencies ranging between 7% and 69% (Table 1).
Knowing the length distribution of the fibril samples allows the calculation of their fibril particle
concentrations (Xue and Radford, 2013). Comparing [PSI+] transfection efficiencies with their corre-
sponding fibril particle concentrations (Figure 5b) revealed a striking correlation, indicating that the
ability of Sup35NM fibril particles to induce the [PSI+] prion phenotype depends on the number of
particles present. Interestingly however, as seen in Figure 5b, this correlation deviated from the
expected linear behavior where 0% [PSI+] prion phenotype would result from a particle concentra-
tion of 0 M (the x-intercept of the dashed line is 12.2 nM in Figure 5b inset), suggesting that fibril
particles are not equally capable at inducing the [PSI+] prion phenotype. This is consistent with the
fact that fibril samples that were not sonicated (Figure 2b, upper left image) cannot induce the
[PSI+] prion phenotype, since the particle concentration for the non-sonicated sample still must be
greater than 0 M. Therefore, our analysis suggests that longer particles are less able to induce the
[PSI+] prion phenotype compared to identical numbers of their shorter counterparts.
There are two possibilities that can explain the observed higher infective potential of short par-
ticles compared with the same number of their longer counterparts; (a) the particles of different
lengths are not equal in recruiting soluble intracellular Sup35 and seeding the conversion and
growth of new amyloid, or (b) the particles are not equally capable of crossing the cell membrane
and access the cellular environment to elicit the [PSI+] phenotype. To test whether the observed dif-
ferences were due to a poor ability of larger particles to seed amyloid growth, we performed
seeded amyloid growth assays monitored by Thioflavin T (Figure 5—figure supplement 2) where 10
uM fresh Sup35NM monomers were seeded by 1% of the fibril samples sonicated to different
extents. The seeding potential of the fibril particles was determined by measuring the initial slope of
the seeded growth curves and the resulting slope value compared with each sample’s known particle
concentration. All samples analyzed were capable of seeding the polymerisation of monomeric
Sup35NM, albeit to different extents, with those sonicated for longer periods doing so with greater
efficiency (Figure 5—figure supplement 2a) as expected for amyloid growth by monomer addition
at fibril ends. As seen in Figure 5—figure supplement 2b (blue data points), and in contrast with
the [PSI+] transfection efficiencies, the seeding ability of the different fibril samples depended solely
on the number of fibril particles, with the initial slope of seeded growth curves showing a linear cor-
relation with particle concentration that was not significantly different to the expected trend where 0
M particles should result in 0 hr 1 initial slope. To further confirm this result, we made a prediction
that seeding with the same particle concentrations using samples of different length distributions
should result in the same seeding efficiency. Here, the average length of particles in sample soni-
cated for 60 s is 145 nm, about twice as long as average length of particles in sample sonicated for
960 s (average length of 75 nm). Therefore, the particle concentration of the sample sonicated for
60 s is roughly half that of the sample sonicated for 960 s. Consequently, an assembly reaction
seeded by 2% of the sample sonicated for 60 s is predicted to be as efficient as the reaction seeded
by 1% of sample sonicated for 960 s. We carried out experiments to test this prediction by seeding
new reactions with 1% as well as 2% of an independent fibril sample sonicated for 60 s (Figure 5—
figure supplement 2b, yellow data points). As seen in Figure 5—figure supplement 2b, a reaction
seeded by 2% of the independent sample sonicated for 60 s (upper right yellow cross) reproduced
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Figure 5. Prion infective potential depends on particle size, concentration and activity. (a) Analysis of prion transfection efficiency. AFM images of
representative Sup35NM fibrils samples sonicated for 15 s (upper) and 960 s (lower) are shown together with plates containing yeast colonies grown
from protoplasts transfected with the Sup35NM fibrils samples, indicating the sample’s ability to infect yeast cells and to induce [PSI+] phenotype in
vivo. Scale bars indicate the length of 1 mm. Individual yeast colonies were scored as [PSI+] (white dots) or [psi-] (red dots) based on their colour in ¼
YEPD and curability in ¼ YEPD supplemented with 3 mM GdnHCl (Figure 5—figure supplement 1). Colonies that showed poor growth or
unrecognisable colour differentiation were omitted (black dots). On each plate, control [PSI+] (white) and [psi-] (red) colonies are present at the upper
right corners for comparison. See Figure 5—figure supplement 1 for the full data set. (b) Dependency of prion transfection efficiency on particle size.
Mean fibril length for each of the 20 samples analysed is plotted against the percentage of S. cerevisiae [PSI+] colonies obtained after prion
Figure 5 continued on next page
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the same efficiency as a reaction seeded with 1% sample sonicated for 960 s (upper right blue cross)
that had a comparable particle concentration. These results rule out that the particles are sufficiently
unequal in seeding the conversion and growth of new amyloid, and therefore suggest that particles
are not equally capable of crossing the cell membrane to access the intracellular environment and
elicit the [PSI+] phenotype.
Next, we investigated how particle size might modulate the relationship between particle concen-
tration and [PSI+] transfection efficiencies. Were transfection efficiency dependent solely on particle
concentration, it would be expected for a transfection efficiency of 0% to occur at 0 M particle con-
centration and increase linearly from that point. This was not the case for our data (dashed line in
Figure 5b). Hence, we propose the introduction of a transfection activity coefficient, gtransf, that is
capable of representing the fibril particles’ infective potential. We then define an active particle con-
centration cp;transf lð Þ depending on the particle length l so that:
cp;transf lð Þ ¼ gtransf lð Þ  cp lð Þ (1)
where cp is the particle concentration and l is particle length. We then assume the simplest possible
model where there is a particle size ‘cut-off’ l, and particles longer than this cut off will not be able
to transfect yeast cells and induce the [PSI+] prion phenotype (i.e. gtransf for an individual particle is 0
when its length is longer than l and one if its length is shorter or equal than l). This can be written















ð Þ  cp lð Þ (3)
To establish the particle size ‘cut-off’ l that is most consistent with our data, we systematically
tested possible l values, and found that when l is 200 nm (Figure 5c) then the calculated activity of
the fibril samples in terms of their active particle concentration satisfies the criteria that it correlates
with the transfection efficiency with the anticipated transfection efficiency of 0% occurring at 0 M
particle concentration (Figure 5d). To test the predictive abilities of this model, we next calculated
the average active particle concentration of the whole sample sonicated for 15 s and 960 s, respec-
tively. For the sample sonicated for 15 s, the particle concentration was estimated to be 22 nM
based on their average length of 210 nm, and the average transfection activity coefficient of this
sample was 0.55 (Figure 5c). According to our model with l = 200 nm, this gives for transfection an
active particle concentration of 12.1 nM. For the sample sonicated for 960 s, the particle
Figure 5 continued
transfection. Inset show dependency of prion transfection efficiency on particle concentration calculated from the length distribution of the samples.
The dashed red line denotes best fit linear model with the slope of 9.3108 M 1 and the intercept of  11.3% with 95% confidence interval for the
intercept between  26.0% to  0.7%, demonstrating that this linear model is not the correct model to describe the transfection efficiency as function of
particle length or particle concentration. (c) Transfection activity of the Sup35NM fibrils samples estimated as the percentage of fibril particles less than
200 nm long show against the average particle length of each fibril sample. Insets show representative particle length distributions of the fibril samples
shown in (a) sonicated for 15 s (blue distribution/arrow) and 960 s (red distribution/arrow), with shaded areas denoting particles larger than 200 nm
long. (d) Dependency of prion infective potential on active particle concentration consisting of fibril particles less than 200 nm long. The red line
denotes best-fit linear model with the slope of 7.6108 M 1.
DOI: https://doi.org/10.7554/eLife.27109.009
The following figure supplements are available for figure 5:
Figure supplement 1. Prion transfection efficiency of Sup35NM amyloid fibrils samples.
DOI: https://doi.org/10.7554/eLife.27109.010
Figure supplement 2. Seeding efficiency of Sup35NM amyloid fibrils samples.
DOI: https://doi.org/10.7554/eLife.27109.011
Figure supplement 3. Testing model predictions on the prion transfection efficiency of Sup35NM amyloid fibrils samples of different length but the
same active concentration.
DOI: https://doi.org/10.7554/eLife.27109.012
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concentration was estimated to be 61 nM from average length of 75 nm, and the average transfec-
tion activity coefficient of this sample was 0.98 (Figure 5c), giving an active particle concentration of
59.8 nM, roughly five times higher than the sample sonicated for 15 s. Consequently, our model pre-
dicts that a five times dilution of a sample sonicated for 960 s will result in the same transfection effi-
ciency as a sample sonicated for 15 s. On the other hand, if our size cut-off model is incorrect and all
effect on transfection efficiency is based purely on the total particle concentration then we expect
five times dilution of a sample sonicated for 960 s will give roughly half the transfection efficiency
compared to that of a sample sonicated for 15 s. We tested this prediction experimentally by mea-
suring the ability of independent samples sonicated for 15 s and 960 s to induce the [PSI+] pheno-
type (Figure 5—figure supplement 3). This experiment confirmed that the transfection efficiencies
of the samples sonicated for 15 s is indistinguishable compared to five times diluted samples soni-
cated for 960 s, which was predicted to have equal active concentration of prion particles. Thus,
these results are consistent with the predictions of our size cut-off model that particles longer than
200 nm in length are likely to be incapable of entering the cells and induce the [PSI+] prion pheno-
type. In reality, the efficiency with which fibril particles enter the cells and propagates the prion phe-
notype may be a continuous and non-linear function of their dimensions. However, our simple
model, with a size cut-off estimate that particles of 200 nm or less in length are capable of entering
the cells and conferring the [PSI+] prion phenotype, is fully consistent with the data. Assuming the
fibril volume is estimated by cylinders of 7.1 nm diameter based on the AFM height data (Figure 4c)
and a fibril density comparable to that of folded proteins at 1.4 g/cm3 (Fischer et al., 2004), then
the molecular weight of a 200 nm particle is approximately 7 MDa. The estimated particle length
cutoff is also corroborated by the AFM images of the sample series, showing fibril clusters persist in
the same size range as our cutoff estimate or larger (e.g. arrows in 15, 30 and 60 s images in
Figure 2b). In summary, these results demonstrate that the infective potential of the Sup35NM prion
samples depends on effective particle concentrations that only take into consideration a subpopula-
tion consisting of prion particles of optimal dimensions for transfection.
Discussion
Infectivity and cell-to-cell propagation are two of the main criteria that set prions apart from other
amyloid aggregates (Tuite and Cox, 2003). Amyloid fibril fragmentation is a crucial process that
potentiates propagation by increasing the number of transmissible, seeding competent particles
and as we demonstrate here, also by producing particles that are of an ‘ideal size’ for transmission.
A growing number of disease-associated amyloid forming proteins appear to possess prion-like
properties in that these amyloid particles can be transmitted to nearby cells to effectively propagate
the amyloid-associated phenotype to previously healthy cells (Aguzzi and Lakkaraju, 2016). These
findings blur the line between transmissible and non-transmissible amyloid, suggesting that the
infectious potential of amyloid is a complex biological property that is better described by a sliding
scale rather than the binary prion/non-prion view.
In the case of the prion-like amyloid proteins such as Ab (Nussbaum et al., 2012), a-synuclein
(Masuda-Suzukake et al., 2013), tau (Sanders et al., 2014), and huntingtin (Pearce et al., 2015),
transmissibility has been linked to a number of active protein import and export mechanisms
(Aguzzi and Lakkaraju, 2016). However, the possibility that cell-to-cell transmission occurs by diffu-
sion across the cellular membrane cannot be discounted. Studies of the mammalian prion protein
PrP have shown that small prion particles consisting of 14–28 PrP monomers are more infections
than their larger counterparts (Silveira et al., 2005), indicating that particle size plays an important
role in mammalian prion infectivity. Furthermore, it has also been shown that exogenous, recombi-
nant Sup35NM amyloid can be used to infect and confer a prion phenotype to mammalian N2a cells
expressing a soluble, cytosolic form of Sup35NM (Krammer et al., 2009). Taken together, these
data indicate that transmissibility might be a general property of all amyloid aggregates, which will
invariably occur given the right physical properties and conditions. This makes it crucial that we fully
understand how the mesoscopic and suprastructural properties of amyloid particles influences their
transmissibility as well as identifying how passive and/or active protein transport mechanisms could
contribute to this phenomenon.
Once formed in a cell, the continued and efficient propagation of a given yeast prion occurs as
cells divide, fuse during mating (Tuite and Cox, 2003) or give rise to the products of meiosis
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(sporulation), and is greatly facilitated by the cytoplasmic location of the transmissible forms of the
prion. This propagation is thought to occur passively by cytoplasmic transfer, as no active mecha-
nisms for transmission of prion particles have yet been identified (Byrne et al., 2009) although the
possibility that extracellular vesicles may facilitate the vertical and horizontal transmission of yeast
prions has been raised (Kabani and Melki, 2015). Infection with amyloid particles can also be
achieved experimentally by transfecting yeast protoplasts that are largely devoid of the normally
protective and robust cell wall (King and Diaz-Avalos, 2004; Tanaka et al., 2004).
In this study, we have taken advantage of the fact that we could quantitatively determine the
lengths of single prion particles using AFM image analysis and calculate particle concentrations. By
then coupling this with yeast transfection we have been able to determine how these properties
affected the efficiency with which they crossed the yeast cell membrane into the cytoplasm and
induce the [PSI+] prion phenotype in vivo. Use of this now well-established yeast prion infection
model has allowed us to systematically investigate how length distribution and particle concentration
affect the activity of amyloid particles to cross cellular membranes and infect yeast cells. The key
conclusion that has emerged from our analysis is that infectivity is only proportional to particle con-
centration when the particles are of favorable size and free from forming aggregate suprastructures
(Figure 6).
Using a simple model to estimate the infectious activity of Sup35NM prion samples based on
their length distribution, we show that the particle concentration versus transfection activity correla-
tion only applies when taking into account an active particle concentration based on prion particles
up to a certain length. This has led us to estimate the size cut-off for infectivity of Sup35NM particles
at approximately 200 nm. Above 200 nm, the individual Sup35NM prion particles are likely to inter-
act and form higher-order aggregate suprastructures (Figure 2b, 0 s, and arrows in 15–60 s), which
bear similarity to what has been described as flocculation or gelation (Buell et al., 2014). The fibrils
in the aggregated suprastructures are relatively inert compared with their shorter, less aggregated
counterparts, and they are non-infectious. Below this size threshold, infectivity is largely dependent
on particle concentration. Thus, the infectious potential of prion samples, in terms of average trans-
fection activity per particle, is likely a non-linear function (e.g. Figure 5c for Sup35NM particles ana-
lyzed here) that depends on the size distribution of the particles (Figure 6). The activity of the
particles as function of their size will subsequently depend on particle-particle interactions coupled
with the mesoscopic properties of the aggregates, and may be further dependent on the particles’
interactions with other cellar components inside cells, on their interactions with membranes and
other surfaces, and on their diffusion properties. In terms of surface interactions, the same active sur-
face that promotes secondary nucleation may also give rise to particle-particle interactions or inter-
actions with membranes and other surfaces (Buell et al., 2014), thus modulating the suprastructure
and infective potential of the particles. In the case of diffusion, the effect of particle size on transla-
tional and rotational diffusion coefficients of rod-like particles are proportional to 1/length and 1/
length3, respectively (Ortega et al., 2003). Therefore, the length dependence of diffusion is consid-
erably larger for small particles roughly below ~50 nm in length compared with their longer counter-
parts (Ortega et al., 2003), suggesting that diffusion may play additional role for the increased
activity of small mobile particles if they are much smaller than ~50 nm. In any case, resolving the
activity function (Equation 2) for other prions and prion-like amyloid systems and understanding the
molecular origins of the constitutive components of this function in order to understand the size–
suprastructure–activity relationships of the amyloid and prion particles will undoubtedly reveal why
some amyloid aggregates are inert while others are cytotoxic and/or infectious.
Successful prion infection depends not only on a particle’s ability to cross the cellular membrane
but also on its interactions with intracellular factors such as chaperones, co-chaperones and the pro-
teostasis machinery in general. These downstream interactions are eventually translated into success-
ful propagation of prions in yeast and in pathogenic prion systems. While our data suggest that the
size threshold and clustering and fibril network formation result in a reduced ability of particles to
cross the cell membrane, further direct observations of prion particles entering the cells and interact-
ing with cellular machineries inside the cell volume will shed light on the role of intracellular pro-
cesses such as chaperone interactions and cellular sequestration or degradation, which may also
influence the effect of particle shape, size and suprastructure on prion propagation. Much like the
data we here show for prion infectivity, intracellular prion propagation in yeast has previously also
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Figure 6. The physical dimensions of prion particles modulate their suprastructure and their infective potential.
The length of individual Sup35NM amyloid fibrils modulate whether they are active prion particles that can infect
cells and induce the [PSI+] prion phenotype or form inactive suprastructures in the form of fibril clusters and
networks. Thus, the infective potential of prion samples may be represented in terms of an average per particle
activity (top sliding bar). Here, the active Sup35NM yeast prion population is represented by an active population
of particles less than ~200 nm long, which are able to cross the membranes of yeast protoplasts and enter the
prion lifecycle in the cells. Particle sizes larger than 200 nm are non-infectious, most likely because they cannot
cross the cell membrane, but this may also be due to the possibilities that they cannot interact with or are actively
sequestered away from the propagation machinery due to their aggregate size.
Figure 6 continued on next page
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been shown to be a ‘size-based’ process (Derdowski et al., 2010), which further emphasizes exis-
tence of physical size barriers in amyloid transmission.
In conclusion, our findings show that the physical dimensions are an important parameter to take
into account when assessing the infective potential of amyloid particles. Since large amyloid fibril
networks are likely to be relatively inert suprastructures compared with small diffusible fibril par-
ticles, calculating size thresholds for effective transmission activity should be of particular importance
when examining the infectious potential of prion-like amyloid structures as well as large structures
such as amyloid plaques, which are thought to be largely inert (Tipping et al., 2015). This leads us
to suggest that strategies to promote pre-formed amyloid assembly into large, non-transmissible
amyloid structures might be able to control their prion-like transmission, and subsequently delay
amyloid disease progression. Further analysis of the size and infective potential of the large amyloid
suprastructures as well as smaller amyloid polymers or particles, which might arise through mechani-
cal or enzymatic action (Powers et al., 2012), will also be crucial in deciphering their fundamental
biological and cellular activities. A molecular understanding of the amyloid fibrils’ stability towards
fragmentation, as well as how fibril fragmentation is catalyzed in the cell by chaperones such as
Hsp104, Hsp70 and Hsp40, will lead us to a better understanding, and suggest diagnostics and ther-
apeutics to combat amyloid transmission, amyloid disease progression and prion infectivity.
Materials and methods
Protein expression and purification
The region of the SUP35 gene encoding the NM region of the yeast Sup35 protein (residues 1–253)
was amplified from plasmid pUKC1620 by PCR and cloned into pET15b as a BamHI-NdeI fragment.
This generated an N-terminal His6-tag fusion protein. The resulting plasmid (pET15b-His6-NM) was
then transformed into the E. coli strain BL21 DE3 (F– ompT gal dcm lon hsdSB(rB- mB-) l(DE3 [lacI
lacUV5-T7 gene 1 ind1 sam7 nin5]). For protein expression, BL21 DE3 was grown overnight in 50 ml
LB supplemented with 0.1 mg/ml ampicillin and then transferred to 1 L cultures of the same medium.
On reaching an OD600 of approximately 0.5, expression was induced with 1 mM IPTG for 4 hr. Cells
were harvested at 6000 rpm and the cell pellets washed once in buffer A1 (20 mM Tris-HCl pH 8.0, 1
M NaCl, 20 mM Imidazole). Cells were pelleted and kept at  80˚C for later use. For the affinity puri-
fication step, buffer A2 (20 mM Tris-HCl pH 8.0, 1 M NaCl, 20 mM Imidazole, 6 M GdnHCl) was
added to the frozen cell pellets at a 5:1 (v/v) ratio, followed by sonication at an amplitude of 22
microns until the cell pellet was completely disrupted. This solution was then subject to centrifuga-
tion at 13000 rpm for 30 min and the resulting supernatant collected. 1 ml of Chelating Sepharose
Fast Flow (GE Healthcare) was added to a small plastic column and prepared for affinity purification
by sequential washing with one column volume (CV) of water, 0.2 M NiCl2, buffer A1 and buffer A2.
The equilibrated resin was then resuspended in buffer A2 and added to the previously collected
supernatant. This mixture was then incubated for 1 hr at room temperature with agitation to improve
protein binding to the affinity resin. Centrifugation at 5000 rpm was subsequently used to collect
the resin, which was then washed in 5 ml buffer A2 and resuspended in buffer A2 and transferred
back to the column. After one wash with 1 CV buffer A2, elution was achieved by addition of 4 ml
buffer A3 (20 mM Tris-HCl pH 8.0, 1 M NaCl, 0.5 M Imidazole, 6 M GdnHCl). The resulting eluate
was immediately used in size-exclusion purification, which was run using a HiLoad 16/600 Superdex
200 pg (GE Healthcare) column in an A¨KTA Prime Plus chromatography system (GE Healthcare). The
eluate was injected into the size-exclusion column previously equilibrated with 1 CV water followed
by 1 CV buffer S1 (20 mM Tris-HCl pH 8.0, 0.5 M NaCl) and 1 CV buffer S2 (20 mM Tris-HCl pH 8.0,
0.5 M NaCl, 6 M GdnHCl). The relevant Sup35NM protein fractions were collected according to the
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Sup35NM fibril formation
For fibril formation, 2.5 ml of 20 mM purified Sup35NM were buffer exchanged into Fibril Forming
Buffer (FFB - 20 mM Na2PO4 pH 7.4, 50 mM NaCl) using a PD-10 column (GE Healthcare) as per
manufacturer’s instructions. Protein concentration was measured using A280 and then adjusted to 10
mM using FFB. Protein was aliquoted into Protein LoBind tubes (Eppendorf) and polymerized at
30˚C (quiescent) for at least 48 hr. For monitoring polymerisation, 100 ml samples of protein were ali-
quoted into black puregrade 96-well plates (BRAND) and Thioflavin T was added to a final concen-
tration of 10 mM. The plate was sealed with Starseal Advanced Polyolefin Film (Starlab) and kinetics
were monitored in a FLUOstar OMEGA plate reader (BMG Labtech) at 30˚C.
Sup35NM fibril fragmentation
Sup35 fibril samples were concentrated by centrifugation at room temperature (13000 rpm, 40 min)
and resuspended in 1:10th of the volume of FFB, unless stated otherwise. Fibril fragmentation was
achieved by sonication over different periods using a probe sonicator (Qsonica Q125) at 20% ampli-
tude in consecutive 5 s on/off cycles on ice cooled water-bath.
Sucrose density gradient analysis
15% to 60% sucrose gradients were prepared in FFB. Fibril samples used in sucrose gradients were
concentrated by centrifugation at room temperature (13000 rpm, 40 min) and then resuspended in
half the volume of FFB before sonication, which was performed as described above. 100 ml of sam-
ples sonicated for different amounts of time were pipetted onto the top of a sucrose gradient and
centrifuged at 31,000 rpm, 4˚C, for 3 hr. Gradients were sampled while on ice by pipetting 221 ml
fractions from the top of the gradient into pre-chilled tubes which were snap-frozen in liquid nitro-
gen and stored at  80˚C for subsequent western blot analysis. Each gradient produced nine frac-
tions. 10 ml of each fraction was analysed on a 4–20% polyacrylamide Tris-Glycine gradient gel
(Invitrogen, Waltham, MA) run at 125 V. Proteins were transferred onto a PVDF membrane by semi-
dry blotting (10 V, 45 min) and membranes were probed with anti-Sup35 (MT50) polyclonal anti-
body. Anti-rabbit HRP-conjugated antibody was used as a secondary antibody in standard ECL anal-
ysis. For densitometry, the image analysis software ImageJ (version 1.42, http://rsbweb.nih.gov/ij/,
RRID:SCR_003070) was used. Relative intensity of each band was calculated by dividing the given
intensity value for each band by the total intensity value for all bands in that sample.
Semi-denaturing agarose gel electrophoresis (SDD-AGE)
SDD-AGE analysis was performed as previously described (Kryndushkin et al., 2003) with the fol-
lowing modifications. Sonicated fibrils were obtained as described above and loaded in a 1.5% aga-
rose gel prepared in buffer G (20 mM Tris, 200 mM glycine) and ran on Laemmli buffer (20 mM Tris,
200 mM glycine, 0.1% SDS). Proteins were transferred using semi-dry blotting and transfer buffer T
(20 mM Tris, 200 mM Glycine, 0.1% SDS, 15% (v/v) methanol) onto a PVDF membrane for 90 min at
10 V. MT50 anti-Sup35 primary antibody was used in western blot analysis as described above. Cell
extracts used in SDD-AGE were prepared by first harvesting yeast cells ( » 2107 cells) and resuspend-
ing the pellet in 100 ml PEB buffer (25 mM Tris-HCl pH 7.5, 50 mM KCl, 10 mM MgCl2, 1 mM EDTA
and EDTA-free Protease Inhibitor Cocktail [Roche]). Approximately one pellet volume of small glass
beads was added to the resuspended cells and lysis performed by vortexing at 4˚C. Lysate was then
cleared by centrifugation (8000 rpm, 10 min, 4˚C) and total protein concentration in the collected
clear lysate was measured by A280. Approximately 100 mg total protein were loaded per lane.
Prion transfection
For prion transfection with synthetic Sup35NM amyloid fibrils, a [psi-] derivative of the yeast strain
74D-694 (MATa ade1-14 trp1-289 his3D 200 ura3-52 leu2-3,112) was used with an adaptation of a
previously published amyloid fibril transformation protocol (Tanaka, 2010). Cells were inoculated in
5 ml YEPD and grown overnight at 30˚C with agitation. They were then diluted into fresh YEPD and
allowed to grow to an OD600 of 0.5. Cells were than washed and resuspended in 12 ml ST buffer (1
M sorbitol, 10 mM Tris-HCl pH 7.5). Spheroplasts were prepared by addition of 600 U of lyticase
(Sigma L4025) and 10 mM DTT and incubated at 30˚C with agitation for 45 min. Spheroplasts were
then harvested by centrifugation (400 xg, 5 min), successively washed with 1.2M sorbitol and STC
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buffer (1.2 M Sorbitol, 10 mM Tris-HCl pH 7.5, 10 mM CaCl2) and then resuspended in 1 ml STC
buffer. Each transformation reaction consisted of 100 ml spheroplast suspension, 2 ml (approximately
1 mg) of plasmid DNA (pRS416), 10 ml single-stranded DNA (10 mg/ml) and 10 ml of freshly sonicated
Sup35NM amyloid fibrils (as described above) or 1 ml of cell extract. This transformation mix was
incubated for 10 min at room temperature and then 0.9 ml of PEG buffer (40% PEG 4000, 10 mM
Tris-HCl pH7.5, 10 mM CaCl2) was added to each transformation. After 30 min at room temperature,
the spheroplasts were collected by centrifugation (400 xg, 5 min), resuspended in 200 ml SOS media
and 20 ml were added to sterile Top agar (-URA synthetic complete media with 2% agar and 1.2 M
Sorbitol) being kept at 48˚C, gently mixed and then poured into agar plates previously prepared
using the same medium. Cells were allowed to grow for 3–4 days and then colonies were individually
picked into 96 well plates containing YEPD. These were grown overnight at 30˚C with agitation and
then replica plated onto ¼ YEPD to check for the [PSI+] prion phenotype and ¼ YEPD supplemented
with 3 mM GdnHCl to eliminate any false positives; 3 mM GdnHCl eliminates the [PSI+] prion
(Tuite et al., 1981). Fragmented amyloid fibrils used in transformation experiments were simulta-
neously prepared for particle size distribution analysis using AFM as described below.
Atomic Force Microscopy
20 ml of the fibril samples were diluted 1:300 and deposited on a freshly cleaved mica disc (Agar Sci-
entific F7013). After 10 min incubation at room temperature, excess sample was removed by wash-
ing with 1 ml of 0.2 mm syringe filtered mQH20 and then dried under a gentle stream of N2. Samples
were imaged using a Bruker Multimode AFM with a Nanoscope V controller and a ScanAsyst probe
(Silicone nitride tip with tip height = 2.5–8 mm, nominal tip radius = 2 nm, nominal spring constant
0.4 N/m and nominal resonant frequency 70 kHz). Images were captured at a resolution of 4.88 nm
per pixel scanned. All images were processed using the Nanoscope analysis software (version 1.5,
Bruker). The image baseline was flattened using third order baseline correction to remove tilt and
bow, and the data was saved as processed image files and raw data files, for recognition by the fibril
tracing software. A larger number of images were collected for low sonication time point samples,
as long fibrils are harder to measure due to a tendency to tangle and associate in larger structures
(see Figure 2b) that dissociate over extended periods of sonication. Processed image files were
opened and analyzed using automated fibril tracing scripts written in Matlab (Xue, 2013).
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